Navigation Links
GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies
Date:2/28/2017

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse platform.

“The combined power of the Trianni and GigaGen technologies will produce an unprecedented pipeline of fully-human antibodies,” said Dave Johnson, PhD, MBA, CEO of GigaGen. “We are confident that the resulting portfolio will have an enormous impact on the field of immuno-oncology.”

The Trianni Mouse has been engineered with genetic loci that are optimized for the expression of antibodies that are entirely human in their variable domains. Because they retain mouse constant regions in their antibody repertoires, the mice are not immunocompromised, but rather exhibit robust lymphocyte development and immune responses.

GigaGen's highly efficient immune repertoire sequencing and expression platform captures full B-cell repertoires and then builds protein display libraries from the repertoires to rapidly validate binding and function. Using GigaGen's technology, a single mouse produces hundreds or thousands of therapeutic candidates, which are rapidly sequenced and validated for binding affinity.

“We are excited to put The Trianni Mouse into the hands of our partners at GigaGen,” said David Meininger, PhD, MBA, CBO of Trianni. “In prior roles in research and in business development, I evaluated many antibody discovery technologies, and believe that GigaGen and Trianni have transformative technologies that together offer enormous potential to rapidly identify new immuno-oncology treatments.”

About Trianni, Inc.
Trianni is a privately held organization, formed in 2010, with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company is headquartered in San Francisco, CA. For more information about Trianni is available through its corporate website, http://www.trianni.com.

About GigaGen
GigaGen is a biopharmaceutical company developing novel antibody and T-cell therapies derived from immune repertoires. GigaGen’s technology platform captures the genetic make-up of the entire immune repertoire, capturing and genetically analyzing B and T-cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has drug discovery projects with several pharmaceutical companies in addition to its own pipeline for development of the first recombinant intravenous immunoglobulin (IVIG) and immuno-oncology therapies. For more information visit GigaGen.

Read the full story at http://www.prweb.com/releases/2017/02/prweb14086333.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. GigaGen Announces Successful Completion of Technical Goals on Four NIH Grant Projects
2. TRIANNI unterzeichnet eine Lizenzvereinbarung mit Janssen über die Verwendung seiner transgenen Mausplattform
3. TRIANNI Signs Licensing Agreement for Transgenic Mouse Platform Use with Janssen
4. TRIANNI Announces Issuance of Russian Federation Patent
5. Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy
6. Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease
7. BioMarin Announces Fourth Quarter and Full Year 2016 Financial Results
8. Greater Gift Initiative Announces Partnership with Compass Research
9. SPIE Announces New Fellows of 2017
10. Origin, Arcadia Announce China Biotechnology Collaboration in Corn
11. Pharma and Biotechnology Consulting Firm Announces European Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
Breaking Biology Technology:
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):